Gamma-glutamyl transferase, alkaline phosphatase and markers of liver fibrosis
liver stiffness, Decreases in mean fibrosis
LIVER FIBROSIS
A marked reduction in gamma-glutamyl transferase (GGT) levels was evident from week 2 with tropifexor 30–90-μg doses and from week 1 with tropifexor 140- and 200-μg doses, which was sustained to end-of-treatment. The LS mean decrease in GGT from baseline at week 12 was higher in the tropifexor 30- (−29.9 U lThere was no meaningful change in liver stiffness by Fibroscan from baseline to end-of-treatment in any tropifexor dose group compared with placebo. A notable change in enhanced liver fibrosis panel score was observed from baseline to end-of-treatment in the tropifexor 60-μg group (−0.25 versus +0.12 (placebo)) and tropifexor 140- and 200-μg groups only (−0.28 and −0.23, respectively, versus −0.07 (placebo)). Decreases in mean fibrosis biomarker test score from baseline to end-of-treatment in tropifexor 10–90-μg groups were not notably different compared with placebo, and neither were the LS mean decreases observed in the tropifexor 140- and 200-μg groups (data not shown).